Physician profile
Imran Bajwa
NPI 1871553222
$4,767.98
in general payments reported to CMS, 2019-2025
29 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $609 · 2021: $494 · 2022: $205 · 2023: $592 · 2024: $665 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.59 |
| Education | $157.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,420.72 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,033.41 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.64 | 2019-2025 | Jascayd, Ofev |
| Genzyme Corporation | $335.28 | 2019-2025 | |
| Grifols USA, LLC | $277.24 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $235.76 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $138.13 | 2020-2024 | Xywav |
| Insmed, INC. | $134.06 | 2020-2025 | Arikayce, Brinsupri |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Axsome Therapeutics, INC. | $91.93 | 2023-2024 | Sunosi |
| Philips North America LLC | $85.24 | 2019-2023 | |
| Verona Pharma, INC. | $80.36 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $59.10 | 2019-2021 | |
| Harmony Biosciences LLC | $58.71 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.21 | 2025 | Glassia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.33 | 2023-2024 | Tezspire |
| Gilead Sciences, INC. | $33.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.80 | 2019 | |
| Merck Sharp & Dohme LLC | $25.16 | 2019 | |
| Genentech USA, INC. | $24.32 | 2019 | |
| Baxter Healthcare | $23.79 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $22.78 | 2023 | Inspire |
| Electromed, INC. | $20.44 | 2019 | |
| Mylan Specialty L.P. | $18.16 | 2023 | Yupelri |
| Resmed Corp | $14.13 | 2020 | |
| Circassia INC. | $14.13 | 2019 | |
| Advanced Respiratory, INC | $12.31 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.21 | 2020 | |
| Paratek Pharmaceuticals, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Bajwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.